These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17056129

  • 21. Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.
    Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A.
    Med Hypotheses; 2017 Feb; 99():57-62. PubMed ID: 28110700
    [Abstract] [Full Text] [Related]

  • 22. New insights into huperzine A for the treatment of Alzheimer's disease.
    Zhang HY.
    Acta Pharmacol Sin; 2012 Sep; 33(9):1170-5. PubMed ID: 22941287
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease.
    Zangara A.
    Pharmacol Biochem Behav; 2003 Jun; 75(3):675-86. PubMed ID: 12895686
    [Abstract] [Full Text] [Related]

  • 32. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment.
    Minarini A, Milelli A, Tumiatti V, Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Motori E, Angeloni C, Hrelia S.
    Neuropharmacology; 2012 Feb; 62(2):997-1003. PubMed ID: 22032870
    [Abstract] [Full Text] [Related]

  • 33. Cholinergic function and Alzheimer's disease.
    Giacobini E.
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S1-5. PubMed ID: 12973744
    [Abstract] [Full Text] [Related]

  • 34. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
    Arce MP, Rodríguez-Franco MI, González-Muñoz GC, Pérez C, López B, Villarroya M, López MG, García AG, Conde S.
    J Med Chem; 2009 Nov 26; 52(22):7249-57. PubMed ID: 19856923
    [Abstract] [Full Text] [Related]

  • 35. [Research progress on Alzheimer's disease: pathogenesis and medical therapy].
    Sheng SL.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr 26; 26(2):101-3. PubMed ID: 15171541
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
    Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2007 Jan 26; 100(2):490-502. PubMed ID: 17144902
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.